Status:
SUSPENDED
A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)
Lead Sponsor:
Nang Kuang Pharmaceutical Co., Ltd.
Conditions:
Pain, Postoperative
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
This study focused on ND-340 extended release injection suspension for patients undergoing total knee arthroplasty with a one-time nerve blockade to assess drug side effects, pharmacokinetics and the ...
Eligibility Criteria
Inclusion
- Subject with age between 20 and 80 (inclusive) years old at the screening visit
- With physician's order to undergo scheduled primary unilateral TKA
- Female subject with childbearing potential must have a negative serum pregnancy test at the screening visit
- Both male and female subjects with childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study with their partners (excluding women who are not of childbearing potential and men who have been sterilized).
- Able and willing to comply with all study visits and procedures
- Able to speak, read, and understand the language of the informed consent form (ICF), study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments
- Willing and capable of providing written informed consent
Exclusion
- Body weight \< 50 kilograms or a morbidly obese (body mass index ≥ 35kg/m2)
- Subject with American Society of Anesthesiologists (ASA) physical status \> 3 at the screening visit
- Undergoing or is plan to undergo bilateral or revision total knee replacement
- Previous contralateral TKA or open knee surgery on the knee being considered for TKA in this study within 1 year prior to screening. Prior arthroscopy at least 1 week prior to TKA is permitted.
- Use of any of the following medications within the time specified before TKA
- Use of any opioid within 24 hours or long-acting opioid within 3 days
- Use of any NSAID including selective COX-2 inhibitor within 3 days
- Use of any selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin (LYRICA®), or duloxetine (CYMBALTA®) within 3 days
- Use of monoamine oxidase inhibitors (MAOIs) within 14 days
- Concurrent painful physical condition, diseases or concurrent surgery that may require analgesic treatment (such as NSAIDs or opioids) in the post-operative period for pain that is not strictly related to the surgery, and which may confound the post-operative assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery)
- Pre-operative liver insufficiency as defined by liver function tests \[i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin\] ≥ 1.5 times the upper limit of normal (ULN) at the screening visit
- Pre-operative renal insufficiency (creatinine clearance \< 60 mL/min) at the screening visit
- Known of active infection with HIV, HBV, or HCV at the screening visit
- With abnormal ECG at screening and admission, which is not suitable to participate into this study as judged by the investigator before TKA
- With abnormal results of sensory examination as judged by the investigator before TKA
- Administration of an investigational drug within 30 days or 5 elimination half- lives of such investigational drug, whichever is longer, prior to study drug administration; or planned administration of another investigational product or procedure during the study period
- Receiving other surgeries within 30 days prior to screening
- Receiving blood transfusion within 30 days prior to screening
- With a history of allergy or hypersensitivity to local anesthetics
- Previous hypersensitivity to or contraindication to any of the pain-control agents planned for surgical or post-operative use in this study (i.e., morphine, bupivacaine, tramadol, and acetaminophen)
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years prior to screening
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that could interfere with study assessments or compliance in the opinion of the investigator
- Current or historical evidence of any clinically significant disease or condition, especially terminal stage cancer, poorly controlled diabetic mellitus (i.e., HbA1c \> 8%), or neurological disease that, in the opinion of the investigator, may increase the risk of study treatment and TKA, or complicate the subject's post-operative course or interfere with the determination of pain intensity related solely to the TKA
- Subject with severe heart diseases (NYHA class-III and IV), with ischemic heart diseases (angina pectoris and myocardial infarction) and subject who underwent percutaneous transluminal coronary angioplasty (PTCA) or had treatments for coronary artery bypass graft within 6 months prior to screening
- With pre-existed psychiatric or neurological deficits, which may compromise the neurological toxicity evaluations in this study by the investigator's judgment
- With stroke within 1 year prior to screening
- With bone cancer within 5 years prior to screening
- Inability to understand or operate the PCA machine
- Female subject who is breast-feeding, pregnant, or planning to become pregnant
Key Trial Info
Start Date :
October 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04515953
Start Date
October 15 2020
End Date
June 1 2026
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nang Kuang Pharmaceutical Co., LTD
Tainan, Taiwan (台灣), Taiwan, 712